Please login to the form below

Not currently logged in
Email:
Password:

Cancer Research

This page shows the latest Cancer Research news and features for those working in and with pharma, biotech and healthcare.

Pfizer and Arvinas announce $1bn deal for investigational oral protein degrader

Pfizer and Arvinas announce $1bn deal for investigational oral protein degrader

cancer with encouraging early clinical data and a potential novel hormonal therapy backbone for HR+ breast cancer,” said Jeff Settleman, chief scientific officer for oncology research and development at Pfizer. ... This partnership complements

Latest news

More from news
Approximately 23 fully matching, plus 357 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 41 partially matching documents found.

Latest appointments

  • ICR appoints Kristian Helin as its new chief executive ICR appoints Kristian Helin as its new chief executive

    Helin will join ICR in September from the Memorial Sloan Kettering Cancer Center in the US. ... The Institute of Cancer Research, London has appointed Kristian Helin (pictured above) as its new chief executive, with the ‘world-leading’ cancer

  • McCann Health France strengthens team with two new hires McCann Health France strengthens team with two new hires

    Initially, she worked on the research and development of new drugs in cardiovascular and metabolic diseases before specialising in oncology and onco-haematology. ... Prior to McCann Health France, she served as scientific director at various

  • F-star hires ex-BMS immuno-oncology leader

    pipeline. As we saw at the recent ASCO meeting, bispecific antibodies are leading a paradigm shift in cancer care and the potential to improve the outcome for cancer patients has never ... He is an active member of the American Society of Clinical

  • Immunocore names new CEO, Nanoform adds to commercial team and Verona hires CMO Immunocore names new CEO, Nanoform adds to commercial team and Verona hires CMO

    Under Bahija’s leadership, MedImmune significantly boosted its pipeline, expanding from 40 to more than 130 molecules in research and development targeting cancer; respiratory, inflammation, and autoimmunity; cardiovascular, renal and metabolic;

  • José Baselga joins BMS’ board of directors José Baselga joins BMS’ board of directors

    Dr Baselga is currently the physician in chief at Memorial Sloan Kettering Cancer Center, where he is responsible for the management of patients care, enhancing and expanding programmes in clinical and ... Association for Cancer Research.

More from appointments
Approximately 1 fully matching, plus 33 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 2 fully matching, plus 36 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Havas Life Medicom

We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...

Latest intelligence

JulAug cover image
The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...
Virtual Speaker Program: A Customer Story
Learn how we helped our client develop a virtual speaker program and roll out a series of regional peer-to-peer education sessions....